Clinical Trial: Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Ability of the New Vero-cell-derived Inactivated Japanese Encephalitis Vaccine (IXIARO) to Elicit a Booster Response in Travellers Previously Vaccinated With Traditional M
Brief Summary:
The old mouse brain derived Japanese encephalitis vaccines (MBJEV) have been reported to cause serious adverse effects and are therefore replaced with the novel Ixiaro vaccine. The present study investigates whether vaccinees primed with MBJEV can be boosted with Ixiaro.
Travellers receiving Japanese encephalitis vaccines are enrolled for a follow-up of immune responses in four groups: A) primary immunization with BMJEV, B) primary and secondary immunizations with MBJEV, C) primary immunizations with Ixiaro and S) Primary immunization with MBJEV and secondary immunization with Ixiaro. Immune responses are followed with help of serum samples collected before and after vaccination.
Detailed Summary:
Sponsor: Helsinki University Central Hospital
Current Primary Outcome: Antibody titers 1 month after last vaccine dose [ Time Frame: 1 month ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Antibody titers two years after vaccination [ Time Frame: 2 years ]
Original Secondary Outcome: Same as current
Information By: Helsinki University Central Hospital
Dates:
Date Received: June 30, 2011
Date Started: January 2008
Date Completion:
Last Updated: October 27, 2011
Last Verified: October 2011
